ABIN250389
antibody from antibodies-online
Targeting: AKAP9
AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO
Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN250389 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9) (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified
- Reactivity
- Human, Rat
- Host
- Goat
- Epitope
- C-Term
- Vial size
- 0.1 mg
- Storage
- Store at -20°C. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes.
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Christian F, Szaszák M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Götz F, Zühlke K, Moutty M, Göttert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Verli J, Gáspár R, Noack C, Bergmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E
The Journal of biological chemistry 2011 Mar 18;286(11):9079-96
The Journal of biological chemistry 2011 Mar 18;286(11):9079-96
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE
The Journal of clinical investigation 2005 Jan;115(1):94-101
The Journal of clinical investigation 2005 Jan;115(1):94-101
No comments: Submit comment
No validations: Submit validation data